Island Pharmaceuticals Share Price and Company Fundamentals
Last traded: Last Friday at 4:47 AM
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development; cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.
Key Metrics
PE ratio
-
PB ratio
3.43
Dividend yield
Beta
-
Market cap
-
Enterprise value
-
Company profile
| Primary activities | Island is a drug development and repurposing company, focused on repurposing and clinical development solutions for viral diseases with no existing therapies. |
|---|---|
| Industry / Sector | Biotechnology / Healthcare |
| Website | https://www.islandpharmaceuticals.com |
| Mailing address | 697 Burke Road Suite 201 Camberwell VIC 3124 Australia |
| Phone / Fax | 61 3 7036 7675 / |
| Share registry | AUTOMIC REGISTRY SERVICES |
Dividends
Island Pharmaceuticals does not pay dividends.
Company Executives
As of Jan 2022, following are the company executives and directors listed on Island Pharmaceuticals.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Paul Donald Richard MacLeman M.B.A., MBA, BVSc, Grad Dip Tech, Grad Cert Eng, G | Exec. Chairman | 55 | 60.45k |
| Dr. David Charles Foster | MD, CEO, Pres & Exec. Director | 77.94k | |
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD | Company Sec. | 58 |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
0.00%
Return on assets
-40.29%
Return on equity
-66.48%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Island Pharmaceuticals is and its enterprise value is .
Companies similar to Island Pharmaceuticals (ILA)
Island Pharmaceuticals (ASX:ILA) Frequently Asked Questions
1. What is Island Pharmaceuticals's Stock Symbol?
Island Pharmaceuticals trades on ASX under the ticker symbol "ILA".
2. What is Island Pharmaceuticals's stock price today?
One share of ILA stock can currently be purchased for approximately $0.265.
3. How can I contact Island Pharmaceuticals?
Island Pharmaceuticals's mailing address is 697 Burke Road Suite 201 Camberwell VIC 3124 Australia. The company can be reached via phone at 61 3 7036 7675.
4. What is Island Pharmaceuticals's official website?
The official website of Island Pharmaceuticals is https://www.islandpharmaceuticals.com.
5. Which share registry manages Island Pharmaceuticals's stock?
Island Pharmaceuticals's stock is managed by AUTOMIC REGISTRY SERVICES.